化疗后消失性肝转移残留病灶评估:AROD研究
AROD研究为单中心前瞻性观察队列,纳入46例结直肠癌肝转移患者共172个化疗后影像学消失的肝转移灶(DLM)。术中可识别者切除并病理检查,未切除者术后影像监测。结果显示9.3%的DLM存在残留病灶,支持基于术中表现的选择性切除策略。
要点
- 约10%的化疗后消失性肝转移灶仍存在残留病灶。
- 切除的DLM中7.5%病理证实残留,未切除者11.0%临床复发。
- 未切除DLM的6个月和12个月累积复发率分别为2.2%和7.7%。
核心结论
- 约10%的DLM存在残留病灶,支持基于术中表现的选择性切除策略,并强调精确影像与术后监测的重要性。
研究设计与样本
- 单中心观察性队列研究,于2020年4月至2024年3月在东京癌症研究所医院开展,纳入46例患者共172个DLM。
- DLM定义为化疗前增强CT或钆-乙氧基苄基-二乙烯三胺五乙酸增强MRI可检出、化疗后两种 modality 均不可见的肝转移灶。
- 术中识别到的DLM予以切除并病理检查,未切除的DLM通过术后影像监测。
主要发现
- 80个切除的DLM中6个(7.5%)病理证实残留病灶;91个未切除DLM中10个(11.0%)显示临床残留病灶。
- 未切除DLM部位的6个月和12个月累积复发率分别为2.2%和7.7%。
- 共计9.3%(95%CI 5.5-14.6%)的DLM确认存在残留病灶。
- 中位无复发生存期为17.4个月,中位总生存期未达到。
临床怎么用
- 对化疗后影像学消失的肝转移灶,可依据术中探查所见决定是否切除,无需一律切除。
- 未切除的DLM需进行严格的术后影像随访,因12个月累积复发率可达7.7%。
- 术前应结合增强CT和钆-乙氧基苄基-二乙烯三胺五乙酸增强MRI精确评估,以指导术中决策。
局限性
- 单中心、观察性设计,样本量有限(46例患者、172个DLM),结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To prospectively assess the incidence of residual disease in disappearing liver metastases (DLM) and evaluate associated oncologic outcomes. SUMMARY BACKGROUND DATA: DLM are colorectal liver metastases that become undetectable on imaging after chemotherapy. Although DLM are increasingly observed with modern systemic therapy and imaging, their clinical significance and appropriate management remain unclear. METHODS: A single-center, observational cohort study conducted at Cancer Institute Hospital, Tokyo, from April 2020 to March 2024. DLM was defined as liver metastases detectable by contrast-enhanced CT or gadolinium-ethoxybenzyl-diethylenetriamine penta acetic acid-enhanced MRI before chemotherapy, but undetectable on both modalities afterward. Intraoperatively identified DLM were resected and pathologically examined. Unresected DLM were monitored by postoperative imaging. RESULTS: A total of 46 patients with 172 DLM were included. Of the 80 resected DLM, six (7.5%) contained pathological residual disease. Of 91 unresected DLM, 10 (11.0%) showed clinically residual disease. The 6- and 12-month cumulative recurrence rates at the DLM site in unresected DLM were 2.2% and 7.7%, respectively. In total, 9.3% (95% confidence intervals: 5.5-14.6%) of DLM were confirmed as residual disease. Twenty-six patients (56.5%) experienced recurrence: nine in the all-resected group and 17 in the unresected group. Among the latter, eight developed recurrence at the same site as their DLM site, and five underwent repeat resection. Median recurrence-free and overall survivals were 17.4 months and 'not reached'. CONCLUSION: Approximately 10% of DLM harbored residual disease. These findings support selective resection strategies based on intraoperative findings and highlight the importance of precise imaging and postoperative surveillance.
引用
- Kobayashi K, Oba A, Kiritani S, et al. Assessment of Residual or Resected Disappearing Liver Metastases After Chemotherapy: The AROD Study. Ann Surg. 2025. PMID: 40880205. doi:10.1097/SLA.0000000000006923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。